
HCPLive 5 Stories in Under 5: Week of 12/28
Key Takeaways
- StimLabs’ Theracor received 510(k) clearance, marking the first umbilical cord–derived wound care device in sheet form.
- Tradipitant was approved as a new pharmacologic option for preventing motion sickness–related vomiting.
An audio recap of the top 5 stories in healthcare news from the week of 12/28-1/3.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown?
Top 5 Healthcare Headlines for December 28-January 3, 2025:
1.
The FDA granted 510(k) clearance to StimLabs’ Theracor, marking the first umbilical cord–derived wound care device available in a sheet formulation.
2.
The FDA approved tradipitant as the first new pharmacologic option in decades for preventing motion sickness–related vomiting.
3.
The FDA issued a CRL for relacorilant, citing the need for additional evidence of effectiveness despite positive findings from completed trials.
4.
The FDA again declined approval of ONS-5010 for wet AMD, reiterating that confirmatory evidence of efficacy is required to support the application.
5.
The FDA accepted and granted Priority Review to the sNDA for AXS-05, advancing a potential new treatment option for agitation in Alzheimer’s disease.























































































